BioStock

Prenumeration

Alligator Bioscience: BioStock: Alligator's CEO on current development and the rights issue

2024-03-21 09:13:38

The recent phase II success with mitazalimab means that Alligator Bioscience can now start preparing for phase III. Besides mitazalimab, the Lund-based biotech also has other promising projects in its pipeline. Now, Alligator is carrying out a SEK 150.9 million rights issue to bring all of the projects even further. BioStock talked to CEO Søren Bregenholt to discuss the rights issue in more depth.

Read the article at biostock.se:

Alligator's CEO on current development and the rights issue - BioStock (https://www.biostock.se/en/2024/03/alligators-ceo-on-current-development-and-the-rights-issue-2/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden